

# Jaya R Trivedi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/532240/publications.pdf>

Version: 2024-02-01

31  
papers

1,434  
citations

394286

19  
h-index

434063

31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1422  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical findings in MuSK antibody positive myasthenia gravis: A U.S. experience. <i>Muscle and Nerve</i> , 2010, 41, 370-374.	1.0	216
2	Mexiletine for Symptoms and Signs of Myotonia in Nondystrophic Myotonia. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1357.	3.8	208
3	Review of the Diagnosis and Treatment of Periodic Paralysis. <i>Muscle and Nerve</i> , 2018, 57, 522-530.	1.0	157
4	Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2344.	3.8	81
5	Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. <i>Brain</i> , 2013, 136, 2189-2200.	3.7	77
6	A randomized trial of mexiletine in ALS. <i>Neurology</i> , 2016, 86, 1474-1481.	1.5	72
7	Painful peripheral neuropathy and its nonsurgical treatment. <i>Muscle and Nerve</i> , 2004, 30, 3-19.	1.0	59
8	Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. <i>Neuromuscular Disorders</i> , 2019, 29, 167-186.	0.3	59
9	Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. <i>Neurology</i> , 2016, 86, 1408-1416.	1.5	53
10	Guidelines on clinical presentation and management of nondystrophic myotonias. <i>Muscle and Nerve</i> , 2020, 62, 430-444.	1.0	53
11	Primary Lateral Sclerosis. <i>Journal of Clinical Neuromuscular Disease</i> , 2005, 7, 1-9.	0.3	40
12	Skeletal Muscle Channelopathies. <i>Neurotherapeutics</i> , 2018, 15, 954-965.	2.1	40
13	Transverse Myelitis in Systemic Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 126.	4.9	35
14	Nondystrophic myotonia: Challenges and future directions. <i>Experimental Neurology</i> , 2014, 253, 28-30.	2.0	29
15	An interactive voice response diary for patients with non-dystrophic myotonia. <i>Muscle and Nerve</i> , 2011, 44, 30-35.	1.0	24
16	North America and South America (NA-SA) neuropathy project. <i>International Journal of Neuroscience</i> , 2013, 123, 563-567.	0.8	24
17	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	1.0	24
18	Adult Polyglucosan Body Disease Associated With Lewy Bodies and Tremor. <i>Archives of Neurology</i> , 2003, 60, 764.	4.9	23

#	ARTICLE	IF	CITATIONS
19	Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS). JAMA Neurology, 2021, 78, 68.	4.5	23
20	Huntington Chorea Presenting With Motor Neuron Disease. Archives of Neurology, 2011, 68, 650-2.	4.9	20
21	Clinical Review of Muscle-Specific Tyrosine Kinase-Antibody Positive Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2007, 8, 217-224.	0.3	18
22	Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. Journal of Clinical Apheresis, 2019, 34, 416-422.	0.7	18
23	A quantitative measure of handgrip myotonia in non&#x2014;dystrophic myotonia. Muscle and Nerve, 2012, 46, 482-489.	1.0	17
24	Muscle Channelopathies. Neurologic Clinics, 2014, 32, 801-815.	0.8	15
25	Hereditary and Acquired Polyneuropathy Conditions of the Peripheral Nerves: Clinical Considerations and MR Neurography Imaging. Seminars in Musculoskeletal Radiology, 2015, 19, 130-136.	0.4	14
26	Trends in authorship based on gender and nationality in published neuroscience literature. Neurology India, 2016, 64, 97.	0.2	14
27	Treatment of Painful Peripheral Neuropathy. Neurologic Clinics, 2013, 31, 377-403.	0.8	9
28	Treatment and Management of Neuromuscular Channelopathies. Current Treatment Options in Neurology, 2014, 16, 313.	0.7	6
29	<scp>Non&#x2014;dystrophic</scp> myotonia: 2&#x2014;year clinical and patient reported outcomes. Muscle and Nerve, 2022, 66, 148-158.	1.0	3
30	Von Hippel-Lindau Disease Associated With Thymoma and Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2005, 7, 59-61.	0.3	2
31	New patient access via telehealth in neuromuscular medicine during COVID-19. Work, 2021, 69, 715-719.	0.6	1